These results indicated that RU486 is a useful tool to demonstrate a stimulatory and inhibitory direct effect of progesterone on ovarian steroidogenesis, exerted most probably at the corpus luteum, affecting its own biosynthesis. The inhibitory effect of progesterone seems to be oestrogen dependent. The existence of a particular intraovarian regulation of progesterone production in rats during pro-oestrus and pregnancy is suggested.
Introduction
The biosynthesis of ovarian progesterone is under hypophysial and placental control, while gonadal steroids modulate the action of gonadotrophins. The regulation of progesterone synthesis and secretion from the ovary has been studied intensively but there is less information regarding the potential actions of this steroid within the ovary. Fanjul et al (1983) suggested that intraovarian actions of steroids such as androgens, oestrogens and progestagens may participate in the local control mechanism by regulating follicular development. For instance, progesterone from the corpus luteum may reversibly inhibit the development of small follicles during the luteal phase. With the decrease in progesterone at the time of luteolysis, further follicular development is resumed (Schreiber et al, 1980) . However, progesterone may stimulate follicular recruitment and development, particularly when serum LH is suppressed (Schreiber and Hsueh, 1979; Richards and Bogovich, 1982; Kim and Greenwald, 1987) . Support for a direct action of progesterone on the ovary is indicated by the presence of specific progesterone receptors in the rat ovary (Schreiber and Hsueh, 1979; Naess, 1981; Schreiber et al, 1983) as well as the mRNA encoding proges¬ terone receptors (Park and Mayo, 1991) . These two facts taken together suggest a possible direct effect of progesterone on ovarian steroidogenesis. Rothchild (1981) proposed that progesterone might regulate its own secretion, and Park and Mayo (1991) suggested that progesterone exerts an important intraovarian function during the preovulatory LH surge and ovulation.
Couët et al. (1990) showed that the last step in progesterone biosyntheis, catalysed by 3ß-hydroxysteroid dehydrogenase (3ß-HSD), is controlled at the level of 3ß-HSD gene expression or the stability of 3ß-HSD mRNA or both factors. Recent studies suggest that the expression of this enzyme is hormonally modulated (Couët et al, 1990; Chedrese et al, 1990; Hawkins et al, 1993) . In particular, rat ovarian 3ß-HSD activity depends on progesterone concentrations (Tanaka el al, 1993) .
RU486 is a synthetic steroid that binds to progesterone receptors acting as a progesterone antagonist (Philibert el al, 1982) without agonist effect (Healy et al, 1983) and is a useful tool for defining the action of progesterone on target organs, both peripherally and centrally (Salicioni et al, 1993; Carón et al, 1994) . The aim of this study was specifically to prevent progesterone action within the ovary through the intrabursal ovarian administration of RU486, in an attempt to address the question of whether the ovary itself is a target tissue for a direct effect of the steroid on ovarian steroidogenesis in the presence or absence of oestrogen. A correlation between luteal 3ß-HSD activity and serum progesterone production was also examined. Preliminary results from part of this study have been presented (Telleria and Deis, 1992) .
Materials and Methods

Animals
Virgin female rats bred in our laboratory (originally Wistar strain) and weighing 180-220 g at the start of the experiments were used. They were kept under controlled conditions of light (lights on from 06:00 to 20:00 h) and temperature (22-24°C); standard rat chow (Nutrie, Cordoba) and water were available ad libitum.
Vaginal smears were taken daily, and only rats with 4 day oestrous cycles were used. Rats were caged individually with fertile males on the night of the pro-oestrous day, and the presence of spermatozoa was checked in the vaginal smear the following morning. This day was designated day 0 of preg¬ nancy. In our laboratory, rats usually give birth on day 22.
All work was in accordance with the NIH Guide for the Care and Use of Laboratory Animals (NIH publication No. 86-23, revised 1985) .
Experimental procedures
The progesterone antagonist dimethyl-aminophenyl]-17a-[l-propynyl]-estra-4,9-diene-3-one; mifepristone: Roussel-Uclaf, Romainville) was administered locally into the ovarian bursa at pro-oestrus and on different days of pregnancy according to the method described by Kannisto et al (1985) . The drug was dissolved in absolute ethanol at a concentration of 1 mmol 1~. Leakage from the bursa was minimized by adding the drug solution in a gel carrier: 0.2 ml of the solution was mixed in 1.8 ml of a 4% solution of methyl cellulose gel (Sigma Chemical Co., St Louis, MO). Both ovaries were exposed through lateral incisions under ether anaesthesia. Each animal received a bilateral intrabursal injection of 25 µ of the gel carrier (control group) or gel carrier with RU486 (1 pg per ovary), between 09:00 and 10:00 h, using a Hamilton microlitre syringe (705-N; Reno, NV). The rats were decapitated 8 h after treatment, except for those on days 3 and 12 of pregnancy when different groups were decapitated at 4, 8 and 24 h after RU486 administration. Two additional groups of animals received a bilateral intrabursal injection of 25 µ per ovary of an undiluted specific progesterone antiserum raised in our laboratory (Salicioni et al, 1993) . The antiserum was mixed in 4% solution of methyl cellulose gel and administered at 09:00-10:00 h on days 12 and 19 of pregnancy. The rats were decapitated 8 h after treatment.
Control rats received the same quantity of normal rabbit serum. Blood was allowed to clot at room temperature and the serum separated and stored at -30°C until assayed for hormones. On days 12 and 19 of gestation, both ovaries were removed from each rat, trimmed of surrounding fat, and the corpora lutea were enucleated and stored at -70°C until assayed for enzymes. Oestradiol benzoate (5 pg per rat; Schering, Buenos Aires) was given s.c. in 0.2 ml of purified sunflower seed oil.
Tamoxifen citrate (Gador, Buenos Aires) in 0.14 mol NaCl 1 " , 0.5% (v/v) Tween 80 was administered per os in two doses of 500 pg kg~' bodymass.
Determination of 3ß-HSD and 20a-HSD activities in corpora lutea
The activities of 3ß-HSD and 20a-HSD were measured according to Kawano et al (1988) with a slight modification. Corpora lutea from each animal were homogenized in 0.7 ml 0.1 mol Tris-HCl \ I mmol EDTA ' (pH 8) at 0°C with a glass homogenizer. The homogenates were centrifuged at carrier ( ) at 09:00-10:00 h to pro-oestrous rats and rats on different days of pregnancy. = Pro-oestrous day.
Values are means ± sem of groups of six to nine animals; a, < 0.05, b, < 0.01, and c, < 0.001 compared with its respective control group by Student's f test.
Statistical analyses
Student's t test was used to assay significant differences between means of two groups. One-way or two-way analysis of variance (anova) followed, respectively, by the Duncan's multiple-range test or the Tau test were used for multiple comparisons. When variances were not homogeneous, logarithmic transformation of data was applied. A value < 0.05 was considered statistically significant.
Results
Serum progesterone concentration on the day of pro-oestrus and on different days of pregnancy after intrabursal ovarian treatment with RU486
Eight hours after RU486 administration, serum progesterone concentration was significantly higher than in controls in pro-oestrous rats and rats at days 3 and 5 of pregnancy (Fig. 1 Towards the end of pregnancy (days [15] [16] [17] [18] [19] [20] , the circulating concentrations of progesterone were significantly higher in the RU486-treated group than in the control group. These high values were similar to those obtained on days 3 and 5 of pregnancy after treatment with RU486. The physiological decrease in serum progesterone concentration on day 21 of pregnancy was not modified by RU486. Groups of pregnant rats were treated with a gel carrier containing saline with or without ethanol to ascertain whether the ethanol used to dissolve RU486 affected progesterone synthesis. Serum progesterone concentration after the intrabur¬ sal ovarian administration of ethanol (144.1 ± 7.5 nmol l~, = 6) was not different from values obtained after saline administration (148.1 ± 6.9 nmol -1, = 7).
Serum prolactin and LH concentrations in pro-oestrus and early pregnancy after intrabursal ovarian RU486 treatment Serum prolactin and LH were measured 8 h after RU486 treatment in different groups of animals to determine whether the modifications of progesterone production after intrabursal ovarian RU486 administration were due to an extraovarian effect of the antiprogesterone on the secretion of luteotrophic hypophyseal hormones. Serum prolactin concentration on the day of pro-oestrus and on days 3, 5, 8 and 9 of pregnancy, measured 8 h after RU486 administration, were not different from serum values in control rats receiving an intrabursal gel carrier (Table 1) . Serum LH concentration in rats at pro-oestrus after RU486 treatment (11.3 ± 2.4 pg 1, = 7) was not different from that of control vehicle-treated rats (10.5 ± 2.4 pg 1 , = 6). Serum LH concentrations were not detectable in early pregnancy in controls and RU486-treated rats. 143.3 ± 13.4 (6) 50.1 ± 11.5 (6) 14.3 ± 3.0 (6) 8.7 ± 2.1 (6) 2.9 ± 0.4 (6) 122.5 ± 15.0 (6) 33.2 ± 13.4 (6) 16.2 ± 2.7 (7) 5.7 ± 1.0(7) 2.5 + 0.2 (6) Rats were treated with either RU486 or gel carrier at 09:00-10:00 h on pro-oestrous day and on days 3, 5, 8 and 9 of pregnancy. Serum prolactin was measured 8 h after treatment. Values are means ± sem for the number of animals in parentheses. at 09:00-10:00 h to rats on day 15 of pregnancy treated with vehicle (Tween; Tween 80) or tamoxifen citrate (Tarn; tamoxifen citrate in two doses of 500 µg kg~' per os at 12:00 h on days 14-15 of pregnancy).
Results are means + sem of groups of six to nine animals. Columns with the same letter differ significantly (a, b: P< 0.01; two-way anova followed by the Tau test).
Serum progesterone concentration after pretreatment with oestrogen, tamoxifen and intrabursal ovarian administration of RU486 The participation of oestrogen in the RU486-induced modi¬ fication of progesterone production was examined by treating two groups of rats with oestradiol benzoate (Fig. 2a ) or tamoxifen citrate (Fig. 2b) . After oestrogen treatment, serum progesterone concentration was significantly higher 8 h after the intrabursal injection of RU486 on day 7 of pregnancy.
Thus, oestrogen treatment reversed the depressed ovarian (0) at 09:00-10:00 h to rats on (a) day 12 or (b) day 19 of pregnancy. Results are means ± sem from six to nine animals; a, < 0.01 compared with gel carrier (one-way anova followed by Duncan's multiple range test). No difference was observed between groups receiving gel carrier with or without normal rabbit serum; therefore all results for control rats have been pooled. progesterone production induced by RU486 in rats pretreated with the vehicle. Oestrogen alone induced a significant increase in serum progesterone, but it was significantly lower than that obtained by combined treatment with oestrogen and RU486. After tamoxifen and RU486 treatment at day 15 of preg¬ nancy, serum progesterone concentration was significantly lower than in tamoxifen and vehicle-treated rats. This low serum progesterone value was significantly different from the high value in serum progesterone induced by the intrabursal ovarian administration of RU486 to rats pretreated with the vehicle.
Activities of luteal enzymes on days 12 and 19 of pregnancy after intrabursal ovarian administration of RU486 or progesterone antiserum 3ß-HSD activity was significantly lower in both RU486 and progesterone antiserum-treated rats on day 12 of pregnancy when compared with the control group (Fig. 3a ). Conversely, after RU486 or progesterone antiserum administration, 3ß-HSD activity was significantly higher than that observed in the control group on day 19 of pregnancy (Fig. 3b) . The decrease or increase of 3ß-HSD activity induced by RU486 treatment showed a good correlation with the simul¬ taneous modifications in serum progesterone concentration (see Fig. 1 ). In neither experimental groups was 20a-HSD activity detectable (results not shown).
Discussion
Ovarian progesterone biosynthesis is primarily controlled by pituitary and placental hormones; however, the possibility of autocrine and paracrine controls of progesterone production in the ovary has been postulated. Rothchild (1965 Rothchild ( , 1981 ined the evidence of the autonomy of the corpus luteum on progesterone secretion in hypophysectomized animals, and suggested that progesterone may modulate its own production at the corpus luteum.
Stimulatory and inhibitory effects of RU486 on progester¬ one biosynthesis have been reported. Thus the spontaneous induction in isolated rat corpora lutea of 20a-HSD, an enzyme that converts progesterone into a derivative devoid of progestational activity (Wiest et al, 1968) , is inhibited by the addition of the progesterone antagonist RU486 to the culture medium (Uilenbroek et al, 1992a) , inducing an increase in progesterone accumulation. However, a direct effect on progesterone biosyn¬ thesis in human granulosa cells, with a significant correlation between increasing doses of RU486 and decreasing progester¬ one production, was demonstrated by Dimattina et al. (1986, 1987) . The results obtained at pro-oestrus and on days 3 and 5, and from days 15 to 20 of pregnancy, suggest intraovarían regulation of progesterone production through negative feedback of the steroid on its own production at the ovary during these reproductive states. These effects of RU486 correlate with the capacity of the synthetic progestin R5020 to inhibit gonadotrophin-stimulated progesterone production in rat granulosa cells (Schreiber et al, 1980) . In contrast to that observed on the other days of pregnancy, the low serum progesterone concentrations obtained when RU486 was administered from day 7 to day 14 may indicate a positive self regulation of progesterone production at this time of preg¬ nancy. These results are in agreement with those obtained by Fanjul et al (1983) , who demonstrated that R5020 enhances gonadotrophin-stimulated progesterone production in rat granulosa cells, exerting a direct stimulatory action on proges¬ terone biosynthesis.
Uilenbroek et al (1992b) observed that RU486 has a negative effect on steroidogenic rat ovarian enzymes and suggested that this is mainly due to lower 3ß-HSD activity. In accordance with this, Tanaka et al (1993) showed a decrease in ovarian 3ß-HSD activity after RU486 treatment in gonadotrophin-primed immature rats. Our results also indicate that RU486 regulates the activity of ovarian 3ß-HSD. The decrease (day 12) and increase (day 19) in luteal 3ß-HSD activity correlate with the respective changes in serum pro¬ gesterone concentrations in rats receiving RU486 into the ovarian bursa. In these rats 20a-HSD, known to have a pivotal role in the mechanism of luteolysis (Wiest and Forbes, 1964;  Bast and Melampy, 1972), was not activated by RU486, indicating that 8 h after intrabursal treatment with the antiprogestagen, the corpora lutea are still active. The mechanism by which RU486 modified 3ß-HSD activity is unknown. We cannot discount the possibility that RU486 acts through a direct interaction with 3ß-HSD. However, it seems likely that RU486 inhibits 3ß-HSD activity, acting as a progesterone receptor antagonist. This contention is supported by the binding of RU486 to progesterone receptors in the cytoplasm of rat granulosa cells (Schreiber and Hsueh, 1979; Schreiber et al, 1983) . Since progesterone receptors have not been found in rat luteal cells, the antiprogestin may act on some other cell type within the ovary, resulting in the production of a factor that modifies luteal progesterone production.
RU486 has a high binding affinity for progesterone and glucocorticoid receptors (Philibert et al, 1982; Moguilewsky et al, 1982) . Both receptors are present in the rat ovary (Schreiber and Hsueh, 1979; Schreiber et al, 1982) . However, the results obtained with the intrabursal ovarian administration of the specific progesterone antibody showing significant changes in 3ß-HSD activity on days 12 and 19 of pregnancy are a good indication that the effect of RU486 on progesterone production is through its antiprogesterone action rather than its capacity to block glucocorticoid receptors.
It is known that prolactin secreted by the pituitary is essential to maintain basal progesterone production in rats during the first week of pregnancy (Gibori and Keyes, 1980) . Therefore, a possible central action of RU486 administered into the ovarian bursa was taken into account. We have demonstrated that systemic administration of 1 or 2 mg of RU486 kg~, doses higher than those administered intrabursally, is not centrally effective in inducing prolactin release in pregnant rats (Deis et al, 1989; Jahn and Deis, 1991; Jahn et al, 1993) . We now show that serum LH and prolactin concentrations in rats at pro-oestrus and on days 3, 5, 8 and 9 of pregnancy are not different from control values. Thus, the increase in serum progesterone noted after the intrabursal ovarian administration of RU486 at pro-oestrus and on different days of pregnancy cannot be attributed to an increase in circulating LH or prolactin. In the present study we did not consider a possible effect of RU486 on the secretion of such placental hormones as placental lactogen or androgens that regulate luteal function during the second half of pregnancy (Gibori et al, 1988) . Progesterone directly decreases placental lactogen II production in vitro (Soares and Glacer, 1987), but it is uncertain whether progesterone is a physiological regulator of placental lactogen production (Soares et al, 1991) . Moreover, the small amount of RU486 administered (1 pg per ovary), as well as the high density of the vehicle used, may exclude a placental effect of the antiprogestin that would otherwise mask a direct ovarian action.
Before egg implantation, there is an increase in serum oestrogen concentrations on day 3 of pregnancy, after which the steroid concentration remains very low until day [15] [16] when it starts to increase progressively until parturition (Yoshinaga et al, 1969; Shaikh, 1971) . The shift of the effect of intrabursal ovarian treatment with RU486 on progesterone production obtained on days 6-7 and 14-15 of pregnancy, seems coincident with either the decrease or increase of oestrogen concentrations in the circulation. The administration of oestradiol on day 6 of pregnancy prevented the shift of the antiprogesterone effect which took place on days 6 and 7 of pregnancy and serum progesterone concentration on day 7 after RU486 treatment was similar to that obtained on days 3 and 5 of gestation. Furthermore, treatment with the oestrogen antagonist, tamoxifen, on days 14 and 15 of pregnancy, prevented the stimulatory effect of RU486 on progesterone production observed on day 15.
The intrabursal ovarian administration of the antiprogesterone RU486 allowed us to postulate the existence of a dual intraovarian regulation by progesterone on its own production.
Moreover, the inhibitory action of progesterone on its own biosynthesis seems to be mediated by oestrogen.
